Invesco Biotechnology & Genome ETFInvesco Biotechnology & Genome ETFInvesco Biotechnology & Genome ETF

Invesco Biotechnology & Genome ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪242.37 M‬USD
Fund flows (1Y)
‪−8.64 M‬USD
Dividend yield (indicated)
0.05%
Discount/Premium to NAV
0.10%
Shares outstanding
‪3.66 M‬
Expense ratio
0.58%

About Invesco Biotechnology & Genome ETF


Brand
Invesco
Home page
Inception date
Jun 23, 2005
Structure
Open-Ended Fund
Index tracked
Dynamic Biotech & Genome Intellidex Index (AMEX)
Management style
Passive
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
Primary advisor
Invesco Capital Management LLC
Distributor
Invesco Distributors, Inc.
PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the funds portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February. Prior to August 28, 2023, the fund traded under the name Invesco Dynamic Biotechnology & Genome ETF.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Multi-factor
Geography
U.S.
Weighting scheme
Tiered
Selection criteria
Multi-factor

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of March 11, 2025
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.86%
Health Technology99.86%
Bonds, Cash & Other0.14%
Mutual fund0.14%
Cash0.00%
Stock breakdown by region
97%2%
North America97.26%
Europe2.74%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows